US FDA to rule on Eliquis in 2nd go-round by 17 March
This article was originally published in Scrip
US drug makers Bristol-Myers Squibb and Pfizer are hoping the luck of the Irish are with them on their on the second go-around with experimental anticoagulant Eliquis (apixaban) at the US FDA, which has set 17 March as the date by which it will rule on whether to approve the medicine as a treatment to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.